Comparison of the effect of topical bevacizumab and sorafenib in experimental corneal neovascularization.
Hakan YıldırımOrhan AydemirMehmet Balbabaİbrahim Hanifi ÖzercanNevin İlhanPublished in: Cutaneous and ocular toxicology (2020)
Sorafenib was as effective as bevacizumab in the regression of corneal neovascularization. The effect of sorafenib seems to be dose-dependent. The low doses and twice a day administration are important advantages of sorafenib.